Malaria Drug is Working with Zinc in USA Trial
- Thread starter O'Royken
- Start date
kane
EOG master
Not a big surprise to anyone familiar with the orange idiot. That pillow guy who got to make a speech the other day donated $100,000 to Trump's campaign. Never change Donald, never change
cheapseats
EOG Master
Let's add up how much Soros contributes to criminal activity of the DNC. I'd guess it exceeds 30m give or take caravan money.
mr merlin
EOG Master
yea, that doesn't mean ventilators, LOL
17 tons is way less than a plane load, it's nothing. a 747 can carry 154 tons. just stop with the nonsense.
Almost Allright
GO Bucks!!!
Another thread goes to shit.
FairWarning
Bells Beer Connoisseur
Happy Passover. Will you attend a packed synagogue tonight?
Sportsrmylife
EOG Master
He is part of the satanic illuminatti. Gates fundes the research for this virus and now wants to profit from the vaccine.
Giant POS
Bigrunner
EOG Master
Thanks,
Can't remember the last time I went to synagogue. I was there over 40 years ago for my Bar Mitzvah. Took that money and became a professional gambler. The rest is history.
Synagogues will be closed this Passover.
TheGuesser
EOG Dedicated
Here's some actual, promising news:
https://www.nejm.org/doi/full/10.1056/NEJMoa2007016
https://thehill.com/policy/healthcare/492322-experimental-covid-19-drug-shows-promise-in-new-study
Experimental COVID-19 drug shows promise in new study
BY TAL AXELROD - 04/10/20 10:23 PM EDT 1,726
1,477
An experimental treatment for the coronavirus showed promise in an early analysis of the drug as the world scrambles for a cure to the highly infectious virus.
According to a report published in the New England Journal of Medicine, Gilead Sciences Inc.’s experimental drug remdesivir was able to effectively treat a number of patients in the U.S., Europe and Canada who needed respiratory support.
The report tracked 53 patients, about half of whom needed mechanical ventilation and four of whom were on a heart-lung bypass machine. Of the 53 patients, 36 saw an improvement in oxygen-support class. Twenty-five people were discharged, while seven died. Mortality was particularly high among those who were on a ventilator.
The patients received the drug through Gilead’s compassionate use program, which is for critically ill patients who are unable to take part in a clinical trial.
“We recognize the limitations of these compassionate use data from a purely investigational perspective, while knowing they are of the greatest significance for the patients whose symptoms improved," said Gilead CEO Daniel O’Day. "These early data from 53 patients have not been generated in a clinical trial and cover only a small portion of the critically ill patients who have been treated with remdesivir."
A number of larger scale trials are underway to study the effect remdesivir has on COVID-19, the disease caused by the novel coronavirus. One trial conducted in China is expected to release results this month, while another from the U.S. National Institutes of Health could report results in the coming weeks.
No treatments are available for the coronavirus, which has infected more than 1.6 million people worldwide and killed more than 100,000.
Scientists are reportedly hopeful that remdesivir, a broad-spectrum antibacterial, could be used to combat COVID-19. A World Health Organization panel said in January that the drug, which was developed initially for Ebola, was particularly promising based on human and animal studies.
https://www.nejm.org/doi/full/10.1056/NEJMoa2007016
https://thehill.com/policy/healthcare/492322-experimental-covid-19-drug-shows-promise-in-new-study
Experimental COVID-19 drug shows promise in new study
BY TAL AXELROD - 04/10/20 10:23 PM EDT 1,726
1,477
An experimental treatment for the coronavirus showed promise in an early analysis of the drug as the world scrambles for a cure to the highly infectious virus.
According to a report published in the New England Journal of Medicine, Gilead Sciences Inc.’s experimental drug remdesivir was able to effectively treat a number of patients in the U.S., Europe and Canada who needed respiratory support.
The report tracked 53 patients, about half of whom needed mechanical ventilation and four of whom were on a heart-lung bypass machine. Of the 53 patients, 36 saw an improvement in oxygen-support class. Twenty-five people were discharged, while seven died. Mortality was particularly high among those who were on a ventilator.
The patients received the drug through Gilead’s compassionate use program, which is for critically ill patients who are unable to take part in a clinical trial.
“We recognize the limitations of these compassionate use data from a purely investigational perspective, while knowing they are of the greatest significance for the patients whose symptoms improved," said Gilead CEO Daniel O’Day. "These early data from 53 patients have not been generated in a clinical trial and cover only a small portion of the critically ill patients who have been treated with remdesivir."
A number of larger scale trials are underway to study the effect remdesivir has on COVID-19, the disease caused by the novel coronavirus. One trial conducted in China is expected to release results this month, while another from the U.S. National Institutes of Health could report results in the coming weeks.
No treatments are available for the coronavirus, which has infected more than 1.6 million people worldwide and killed more than 100,000.
Scientists are reportedly hopeful that remdesivir, a broad-spectrum antibacterial, could be used to combat COVID-19. A World Health Organization panel said in January that the drug, which was developed initially for Ebola, was particularly promising based on human and animal studies.
FairWarning
Bells Beer Connoisseur
I should have realized that everything was closed except for conglomerate shopping centers with our safety in mind.Thanks,
Can't remember the last time I went to synagogue. I was there over 40 years ago for my Bar Mitzvah. Took that money and became a professional gambler. The rest is history.
Synagogues will be closed this Passover.
SlipperyPete
EOG Dedicated
Wonder if Trump is gonna tout this one?
If he is not an investor in the company, I guess we deep down know the answer